Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Wegovy will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a ...

The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a ...

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

Novo Nordisk decodes India’s obesity drug market with Wegovy positioned as once-a-week novel weight management medication: ...

Wegovy is being made available in five dosing strengths with an easy-to-use pen device, which does away the use of syringes ...